Linked Life Data

1387775

Source:http://linkedlifedata.com/resource/pubmed/id/1387775

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
1992-10-7
pubmed:abstractText
We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin. Out of 84 cases where anti-emetic effects were evaluated, numbers of cases assessed as excellent and good were 36 (83.3%) and 34 (40.5%), respectively, the efficacy rate being 83.3% (70/84). Side effects, such as moderate constipation (3 cases) and mild headache (3 cases), were observed in 8/85 cases (9.4%). Abnormalities in clinical laboratory findings including elevation of hepatic function and uricacid values and increase in eosinocyte counts, were observed in 3/85 cases (3.5%). As to overall safety, 78/85 cases (91.8%) were evaluated as having no problem in safety, and 7/85 cases (8.2%), as having minor problem in safety. As to clinical usefulness based on anti-emetic effect and overall safety, out of 79 cases the drug was assessed as very useful in 29 cases (36.7%) and useful in 35 cases (44.3%), the rate of "useful" or above being 81.0% (64/79). Furthermore, when ondansetron was administered in 3 courses of chemotherapy, though the number of patients was small, it was shown that anti-emetic effect of ondansetron did not decline and no problem in safety was observed. From the above, ondansetron which exerted adequate anti-emetic effect in 4 mg once daily doses was considered as a useful and safe anti-emetic in treatment of nausea and emesis associated with cancer chemotherapy.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
1891-903
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:1387775-Administration, Oral, pubmed-meshheading:1387775-Adolescent, pubmed-meshheading:1387775-Adult, pubmed-meshheading:1387775-Aged, pubmed-meshheading:1387775-Aged, 80 and over, pubmed-meshheading:1387775-Antiemetics, pubmed-meshheading:1387775-Antineoplastic Agents, pubmed-meshheading:1387775-Breast Neoplasms, pubmed-meshheading:1387775-Cyclophosphamide, pubmed-meshheading:1387775-Doxorubicin, pubmed-meshheading:1387775-Drug Administration Schedule, pubmed-meshheading:1387775-Female, pubmed-meshheading:1387775-Humans, pubmed-meshheading:1387775-Imidazoles, pubmed-meshheading:1387775-Leukemia, pubmed-meshheading:1387775-Lymphoma, pubmed-meshheading:1387775-Male, pubmed-meshheading:1387775-Middle Aged, pubmed-meshheading:1387775-Nausea, pubmed-meshheading:1387775-Ondansetron, pubmed-meshheading:1387775-Safety, pubmed-meshheading:1387775-Tablets, pubmed-meshheading:1387775-Vomiting
pubmed:year
1992
pubmed:articleTitle
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
pubmed:affiliation
Dept. of Internal Medicine IV, Teikyo University School of Medicine, Kawasaki, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Multicenter Study